Table 3.

Physicochemical characterization of bevacizumab-loaded albumin nanoparticles. PDI polydispersity index, EE encapsulation efficiency, B-NP bevacizumab loaded in albumin nanoparticles, B-NP-P bevacizumab-loaded nanoparticles coated with PEG35, B-DS-NP-P albumin nanoparticles containing the bevacizumab-DS complex coated with PEG35, B-DOCU-NP-P albumin nanoparticles containing the bevacizumab-DOCU complex coated with PEG35. Data expressed as mean ± SD (n = 6). Bevacizumab was quantified by ELISA

	Size (nm)	PDI	Zeta potential (mV)	EE (%)	Payload (µg/mg NP)
B-NP	225 ± 5	0.06 ± 0.02	− 36 ± 2	82 ± 2	61 ± 3
B-NP-P	235 ± 2	0.12 ± 0.03	− 28 ± 4	89 ± 5	46 ± 4
B-DS-NP-P	270 ± 6	0.13 ± 0.03	− 29 ± 4	90 ± 2	43 ± 1
B-DOCU-NP-P	328 ± 32	0.19 ± 0.08	− 26 ± 5	70 ± 6	35 ± 3